03:48 PM EST - Acasti Pharma : announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Pharmacokinetic (PK) trial of CaPre® in the U.S. Acasti Pharma
shares V.APO are trading down $0.05 at $2.00.
